Core Viewpoint - Catheter Precision, Inc. has announced a definitive agreement to divest its atherectomy catheter technologies, enhancing capital efficiency and focusing on its high-growth electrophysiology platform [1][2]. Strategic Rationale - The transaction is expected to accelerate execution across the electrophysiology product portfolio while maintaining exposure to the future commercial success of the divested technologies [4]. Transaction Highlights - The company will receive an upfront cash payment of $15 million upon closing [7]. - It will retain a 5% equity stake in the acquiring company, with anti-dilution protection for up to $5 million of additional equity capital invested [7]. - A ten-year royalty payments agreement will be established, starting with a 1.5% baseline that increases to 3% on quarterly net sales exceeding $5 million [7]. - The transaction is designed to create potential long-term equity upside participation and recurring revenue through performance-based royalties [7]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on advancing the treatment of cardiac arrhythmias through innovative electrophysiology technologies developed in collaboration with leading physicians [5].
Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth